Racial Disparities in Outcomes for High-grade Uterine Cancer: A California Cancer Registry Study
Overview
Affiliations
Background: Endometrial cancer (EC) is the most common gynecologic malignancy. We examined factors affecting overall prognosis and survival among different racial groups diagnosed with high-grade EC.
Methods: We utilized the California Cancer Registry database (CCR) to identify women with high-grade II EC from 1998 to 2009. Using the Kaplan-Meier method, we described disease-specific survival. Survival by stage, race, and time to treatment category was compared using the log-rank test. The associations of race with disease-specific survival were modeled using Cox proportional hazards regression. Covariates were selected a priori.
Results: A total of 10 647 patients met study eligibility criteria. The majority of patients in this cohort of high-grade EC were non-Hispanic (NH) white (64.1%), followed by Hispanic (15.7%), Asian (10.4%), and NH black (9.8%). NH black women had higher incidence of certain aggressive histologic subtypes in comparison with NH whites, including serous carcinomas and carcinosarcoma. Non-Hispanic black patients had a worse 5-year disease-specific survival (DSS) when compared to other racial groups. The five-year DSS for NH black women was 54% (51%-57%), compared to NH white women 66% (65%-67%), Hispanic 67% (64%-69%), and Asians 69% (67%-72%) (P < 0.0001). This clear survival disadvantage of NH black women persisted when controlling for other factors.
Conclusions: Non-Hispanic black women have a higher incidence of more aggressive histologic subtypes even among a cohort of women high-grade EC and have a disproportionately worse disease-specific survival after controlling for factors such as age, histologic subtype, stage, time to treatment, and type of treatment.
Haruna I, Broaddus R, Gladden A, Subedi K, Obeng-Gyasi E Int J Environ Res Public Health. 2025; 22(2).
PMID: 40003471 PMC: 11855543. DOI: 10.3390/ijerph22020245.
Smyth S, Ripullone K, Zouridis A, Pappa C, Spain G, Gkorila A Cancers (Basel). 2025; 17(4).
PMID: 40002230 PMC: 11853231. DOI: 10.3390/cancers17040635.
Olorunfemi G, Libhaber E, Ezechi O, Musenge E PLoS One. 2025; 20(1):e0313487.
PMID: 39854486 PMC: 11759400. DOI: 10.1371/journal.pone.0313487.
Wijayabahu A, McGee-Avila J, Shiels M, Harsono A, Arend R, Clarke M Cancers (Basel). 2024; 16(15).
PMID: 39123474 PMC: 11311553. DOI: 10.3390/cancers16152747.
Szabo Yamashita T, Williams-Perez S, Ehsan S, Mulder M, Kronenfeld D, Huang C Thyroid. 2024; 34(9):1117-1125.
PMID: 38984944 PMC: 11698660. DOI: 10.1089/thy.2024.0239.